Intracranial Arterial Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major intracranial arterial diseases markets are expected to exhibit a CAGR of 3.92% during 2024-2034.
The intracranial arterial diseases market has been comprehensively analyzed in IMARC's new report titled "Intracranial Arterial Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intracranial arterial diseases refer to a group of conditions that primarily affect the arteries inside the brain. These ailments involve the narrowing, blockage, or weakening of the blood vessels that deliver nutrients and oxygen to the brain. The general symptoms commonly associated with the illnesses include frequent or severe headaches, changes in vision, vertigo, dizziness, mood swings, depression, irritability, memory problems, difficulty concentrating, alterations in thinking abilities, confusion, weakness, paralysis, trouble with speech or language, etc. In some cases, these conditions can lead to seizures, manifesting as uncontrolled movements, convulsions, or altered consciousness. The diagnosis of intracranial arterial diseases typically requires a combination of the patient’s clinical features, medical history, and neurological examination. Numerous imaging techniques, like magnetic resonance angiography, computed tomography scans, digital subtraction angiography, etc., are recommended to visualize the bloodstreams in the brain and detect abnormalities. The healthcare provider may further perform an electroencephalogram (EEG) to evaluate electrical impulses in the central nervous system for diagnosing conditions that may cause seizures or various other irregular brain activities.
The increasing cases of atherosclerosis, which can lead to narrowing or complete blockage of the arteries due to the deposit of fatty substances called plaques within the blood vessels, are primarily driving the intracranial arterial diseases market. In addition to this, the rising incidences of various associated risk factors, such as genetic predisposition, high blood pressure, smoking, certain connective tissue disorders, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of radiosurgery, that uses highly focused radiation beams to target and treat vascular malformations without the need for open surgery, is further bolstering the market growth. Apart from this, the inflating application of intravenous thrombolysis procedures, since they involve administering a clot-dissolving medication called tissue plasminogen activator (tPA) to restore blood supply to the brain and improve treatment outcomes in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of embolization devices, which can help to divert the blood flow away from the weakened vessel wall, thereby promoting its healing, is expected to drive the intracranial arterial diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the intracranial arterial diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for intracranial arterial diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intracranial arterial diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the intracranial arterial diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the intracranial arterial diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current intracranial arterial diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the intracranial arterial diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the intracranial arterial diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the intracranial arterial diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of intracranial arterial diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of intracranial arterial diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of intracranial arterial diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with intracranial arterial diseases across the seven major markets?
What is the size of the intracranial arterial diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of intracranial arterial diseases?
What will be the growth rate of patients across the seven major markets?
Intracranial Arterial Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for intracranial arterial diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intracranial arterial diseases market?
What are the key regulatory events related to the intracranial arterial diseases market?
What is the structure of clinical trial landscape by status related to the intracranial arterial diseases market?
What is the structure of clinical trial landscape by phase related to the intracranial arterial diseases market?
What is the structure of clinical trial landscape by route of administration related to the intracranial arterial diseases market?
The intracranial arterial diseases market has been comprehensively analyzed in IMARC's new report titled "Intracranial Arterial Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intracranial arterial diseases refer to a group of conditions that primarily affect the arteries inside the brain. These ailments involve the narrowing, blockage, or weakening of the blood vessels that deliver nutrients and oxygen to the brain. The general symptoms commonly associated with the illnesses include frequent or severe headaches, changes in vision, vertigo, dizziness, mood swings, depression, irritability, memory problems, difficulty concentrating, alterations in thinking abilities, confusion, weakness, paralysis, trouble with speech or language, etc. In some cases, these conditions can lead to seizures, manifesting as uncontrolled movements, convulsions, or altered consciousness. The diagnosis of intracranial arterial diseases typically requires a combination of the patient’s clinical features, medical history, and neurological examination. Numerous imaging techniques, like magnetic resonance angiography, computed tomography scans, digital subtraction angiography, etc., are recommended to visualize the bloodstreams in the brain and detect abnormalities. The healthcare provider may further perform an electroencephalogram (EEG) to evaluate electrical impulses in the central nervous system for diagnosing conditions that may cause seizures or various other irregular brain activities.
The increasing cases of atherosclerosis, which can lead to narrowing or complete blockage of the arteries due to the deposit of fatty substances called plaques within the blood vessels, are primarily driving the intracranial arterial diseases market. In addition to this, the rising incidences of various associated risk factors, such as genetic predisposition, high blood pressure, smoking, certain connective tissue disorders, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of radiosurgery, that uses highly focused radiation beams to target and treat vascular malformations without the need for open surgery, is further bolstering the market growth. Apart from this, the inflating application of intravenous thrombolysis procedures, since they involve administering a clot-dissolving medication called tissue plasminogen activator (tPA) to restore blood supply to the brain and improve treatment outcomes in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of embolization devices, which can help to divert the blood flow away from the weakened vessel wall, thereby promoting its healing, is expected to drive the intracranial arterial diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the intracranial arterial diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for intracranial arterial diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intracranial arterial diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the intracranial arterial diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the intracranial arterial diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current intracranial arterial diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the intracranial arterial diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the intracranial arterial diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the intracranial arterial diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of intracranial arterial diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of intracranial arterial diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of intracranial arterial diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with intracranial arterial diseases across the seven major markets?
What is the size of the intracranial arterial diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of intracranial arterial diseases?
What will be the growth rate of patients across the seven major markets?
Intracranial Arterial Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for intracranial arterial diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intracranial arterial diseases market?
What are the key regulatory events related to the intracranial arterial diseases market?
What is the structure of clinical trial landscape by status related to the intracranial arterial diseases market?
What is the structure of clinical trial landscape by phase related to the intracranial arterial diseases market?
What is the structure of clinical trial landscape by route of administration related to the intracranial arterial diseases market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRACRANIAL ARTERIAL DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTRACRANIAL ARTERIAL DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTRACRANIAL ARTERIAL DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 INTRACRANIAL ARTERIAL DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTRACRANIAL ARTERIAL DISEASES - UNMET NEEDS
10 INTRACRANIAL ARTERIAL DISEASES - KEY ENDPOINTS OF TREATMENT
11 INTRACRANIAL ARTERIAL DISEASES - MARKETED PRODUCTS
11.1 List of Intracranial Arterial Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 INTRACRANIAL ARTERIAL DISEASES - PIPELINE DRUGS
12.1 List of Intracranial Arterial Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. INTRACRANIAL ARTERIAL DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTRACRANIAL ARTERIAL DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTRACRANIAL ARTERIAL DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Intracranial Arterial Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Intracranial Arterial Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Intracranial Arterial Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Intracranial Arterial Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Intracranial Arterial Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Intracranial Arterial Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Intracranial Arterial Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Intracranial Arterial Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Intracranial Arterial Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Intracranial Arterial Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Intracranial Arterial Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Intracranial Arterial Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Intracranial Arterial Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Intracranial Arterial Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Intracranial Arterial Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Intracranial Arterial Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
16 INTRACRANIAL ARTERIAL DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTRACRANIAL ARTERIAL DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTRACRANIAL ARTERIAL DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRACRANIAL ARTERIAL DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTRACRANIAL ARTERIAL DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTRACRANIAL ARTERIAL DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 INTRACRANIAL ARTERIAL DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTRACRANIAL ARTERIAL DISEASES - UNMET NEEDS
10 INTRACRANIAL ARTERIAL DISEASES - KEY ENDPOINTS OF TREATMENT
11 INTRACRANIAL ARTERIAL DISEASES - MARKETED PRODUCTS
11.1 List of Intracranial Arterial Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 INTRACRANIAL ARTERIAL DISEASES - PIPELINE DRUGS
12.1 List of Intracranial Arterial Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. INTRACRANIAL ARTERIAL DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTRACRANIAL ARTERIAL DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTRACRANIAL ARTERIAL DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Intracranial Arterial Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Intracranial Arterial Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Intracranial Arterial Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Intracranial Arterial Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Intracranial Arterial Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Intracranial Arterial Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Intracranial Arterial Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Intracranial Arterial Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Intracranial Arterial Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Intracranial Arterial Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Intracranial Arterial Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Intracranial Arterial Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Intracranial Arterial Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Intracranial Arterial Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Intracranial Arterial Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Intracranial Arterial Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Intracranial Arterial Diseases - Access and Reimbursement Overview
16 INTRACRANIAL ARTERIAL DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTRACRANIAL ARTERIAL DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTRACRANIAL ARTERIAL DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
